Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04808323 · ClinicalTrials.gov registry record · Phase 1
MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
A Phase 1 study of Rectal Adenocarcinoma, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT04808323: Recruiting Phase 1 study of Rectal Adenocarcinoma, sponsored by Medical College of Wisconsin.
NCT04808323 is a Phase 1 study of Rectal Adenocarcinoma that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 22 participants, below the 123-participant average among 17 other Rectal Adenocarcinoma trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04808323, a Phase 1 study of Rectal Adenocarcinoma, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a prospective, open-label, phase I design.
Primary Outcome
This will be measured by NCI Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grades 3, 4 and 5 will be serious.
Conditions Studied
Interventions
- DRUG Capecitabine
- DEVICE Initial Dose of Radiation before Dose Escalation
- DEVICE Cohort A: Dose Escalation Radiation
- DEVICE Cohort B: Dose Escalation Radiation
- DEVICE Cohort C: Dose Escalation Radiation
Study Locations (1)
Wisconsin
- Froedtert & the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-06-17 |
| Est. Completion | 2029-01-20 |
| Phase | Phase 1 |
What NCT04808323 shows while recruiting
NCT04808323 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 123-participant average among 17 other Rectal Adenocarcinoma trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Rectal Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Capecitabine is the first listed.
NCT04808323 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04808323 about?
NCT04808323 is a clinical study titled "MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer". This study is a prospective, open-label, phase I design.
What is the current status of trial NCT04808323?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2021-06-17. Estimated completion is 2029-01-20.
What conditions does trial NCT04808323 study?
This clinical trial studies the following conditions: Rectal Adenocarcinoma.
What interventions are being tested in trial NCT04808323?
The interventions under investigation include: Capecitabine (DRUG), Initial Dose of Radiation before Dose Escalation (DEVICE), Cohort A: Dose Escalation Radiation (DEVICE), Cohort B: Dose Escalation Radiation (DEVICE), Cohort C: Dose Escalation Radiation (DEVICE).
Who is sponsoring clinical trial NCT04808323?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04808323 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04808323's enrollment target sits among peer trials
22 15th of 17 higher than 3 of 17 other Rectal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rectal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
RECRUITING · Phase 1
-
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
COMPLETED · Phase 1
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
RECRUITING · Phase 2
-
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy